title: Risk organ + LCH gets the one-two punch?
abstract: In this issue of Blood, Donadieu et al present what may be the most encouraging data to date on a group of patients with Langerhans cell histiocytosis (LCH), which historically has poor disease-free survival and poor overall survival.
authors.affiliation: ARKANSAS CHILDREN'S HOSPITAL.
authors.forename: Kimo C
authors.identifier: http://orcid.org/0000-0002-1342-7287
authors.initials: KC
authors.lastname: Stine
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017338:Cladribine / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003561:Cytarabine; D017338:Cladribine